Objective: The systematic review aims to identify common pairs of adverse drug-drug interactions (DDIs) in hospital treatment based on published research findings worldwide from 2022 to 2023.
Materials and methods: Utilize specific command syntax to search and filter on PubMed for full-text studies in English that focus on the DDI rates, published during the period 2022-2023.
Results: A total of 393 different DDI pairs were recorded from 20 articles that met the study inclusion criteria. The most frequent DDI pair was lorazepam + olanzapine (55.5%). Ritonavir was the most frequently implicated drug, involved in 24 out of 393 DDI pairs (6.1%). Eleven DDI pairs were listed in the "Issuance of the list of contraindicated drug interactions in clinical practice at healthcare facilities" (Decision No. 5948/QD-BYT). Among these, erythromycin + fluconazole and ceftriaxone + calcium gluconate were the most commonly prescribed, with the rates of 33.6% and 25.0%, respectively.
Conclusions: The prescription of interacting drugs remains a critical concern in clinical practice. Many DDI pairs observed in hospitals worldwide are not included in Decision No. 5948/QD- BYT (2021). Therefore, healthcare professionals need to regularly update their knowledge of drug interations from various sources to optimize decision-making for the prevention and resolution of DDIs, thereby ensuring patient safety during treatment.
2. SYSTEMATIC REVIEW OF THE PREVALENCE OF DRUG INTERACTIONS IN HOSPITAL SETTINGS FOR THE PERIOD OF 2022-2023
63
Views
16
Downloads
Keywords
Drug-drug interactions, Decision No. 5948/QD-BYT, systematic review, Lexicomp.
Abstract
References
[1]
Askari M ES, Louws M, Wierenga PC et al, Fre- quency and nature of drug-drug interactions in the intensive care unit. Pharmacoepidemiology and drug safety. 2013, 22(4): 430 - 437.
Google Scholar
[2]
Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. Journal of clin- ical pharmacy and therapeutics. 2008, 33(2): 141- 151.
Google Scholar
[3]
Perić A, Udilović A, Dobrić S et al., The impact of treatment choices on potential drug-drug in- teractions in hypertensive patients. British jour- nal of clinical pharmacology, 2022, 88(5): 2340 - 2348.
Google Scholar
[4]
Nguyễn Thị Ngọc Diễm, Phạm Thành Suôl, Nguyễn Thiên Vũ và cộng sự, Tương tác thuốc trong đơn thuốc điều trị ngoại trú-nội trú và yếu tố liên quan tại bệnh viện Trường Đại học Y Dược Cần Thơ năm 2021-2022. Tạp chí Y Dược học Cần Thơ, 2022, 51: 236 – 244.
Google Scholar
[5]
Roblek T, Vaupotic T, Mrhar A et al., Drug- drug interaction software in clinical practice: A systematic review. European journal of clinical pharmacology, 2015, 71(2): 131 - 142.
Google Scholar
[6]
Bộ Y tế, Quyết định số 5948/QĐ-BYT. Quyết định về việc ban hành danh mục tương tác thuốc chống chỉ định trong thực hành lâm sàng tại các cơ sở khám bệnh, chữa bệnh, 2021: 2-3.
Google Scholar
[7]
Liu Y, Yang M, Ding Y et al., Clinical signifi- cance of potential drug-drug interactions in older adults with psychiatric disorders: A retrospective study. BMC psychiatry, 2022, 22(1): 563.
Google Scholar
[8]
Mills KT, Stefanescu A, He J, The global epi- demiology of hypertension. Nature reviews Ne- phrology, 2020, 16(4): 223 - 237.
Google Scholar
[9]
Li T, Hu B, Ye L et al., Clinically Significant Cytochrome P450-Mediated Drug-Drug Inter- actions in Children Admitted to Intensive Care Units. International journal of clinical practice, 2022, 2786914.
Google Scholar
[10]
Nawaz HA, Khan TM, Adil Q et al., A Prospec- tive Study of Medication Surveillance of a Pedi- atric Tertiary Care Hospital in Lahore, Pakistan. Pediatric reports, 2022, 14(2): 312 - 319.
Google Scholar